No question about it, the lung cancer field is hot—and chock-full of new drugs and combos. But there's a dearth of treatments specifically for early-stage disease, and Johnson & Johnson is looking to crowdsourcing to bring in new ideas.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,